December 23, 2024
TOPLINE: Age-standardized mortality rates for hepatocellular carcinoma (HCC) in the United States are expected to rise from 5.03 per 100,000 persons in 2022 to 6.39 per […]
December 23, 2024
TOPLINE: Short-course vaginal cuff brachytherapy (VCB) demonstrated noninferiority in quality of life for patients with early endometrial cancer vs standard regimens, in a prospective randomized trial. […]
December 23, 2024
SAN DIEGO — Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer product to become the […]
December 23, 2024
Do patients with early-stage non–small cell lung cancer (NSCLC) benefit from continuing immunotherapy beyond surgery? The short answer: Oncologists don’t know for sure. Since October 2023, […]
December 20, 2024
TOPLINE: SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time […]
December 19, 2024
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-vs-host […]
December 19, 2024
In recent years, hypofractionated radiation has eclipsed conventionally fractionated radiation as the preferred treatment option for a range of cancer types, including early breast, prostate, lung, […]
December 19, 2024
Patients with mantle cell lymphoma (MCL) who show undetectable minimal residual disease (MRD) after initial treatment with chemotherapy show no significant overall or progression-free survival benefit […]
December 19, 2024
Clinicians frequently reach out to Catherine Varney, DO, asking if it’s safe to prescribe glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to patients with thyroid disorders, […]